Proteolytic Activity of MSP. A colorimetric assay was used to determine the proteolytic activity of MSP, with hide powder azure as the substrate and trypsin as the standard. Hide powder azure (50 mg) was dissolved in 2 ml diluting buffer consisting of 0.1 M sodium phosphate, 0.001 M zinc sulfate, 0.02% sodium azide, pH 6.0. Dilutions of MSP and trypsin dialyzed to diluting buffer, or diluting buffer alone as a blank, were added in 200-1.d aliquots to the hide powder azure mix, and the mixture was rotated at 140 rpm at 37'C for 30 min. The mixture was then chilled to 4°C to stop the reaction and subjected to centrifugation at 1,400 g for 10 min at VC . The colored supernatant solution was aspirated, and the OD read at 595 nm on an ultrospec 4050 spectrophotometer (LKB Instruments, Inc., Gaithersburg, MD), setting the OD of the blank to zero. A standard curve of proteolytic activity (OD) versus mass for trypsin was constructed . One tryptic unit (TU) was defined as the proteolytic activity of 1 lcg of trypsin . The proteolytic activity of MSP was derived from the standard curve . The experiment was performed in duplicate.
Immunization of Guinea Pigs with MSP. MSP was dialyzed at 4°C overnight in a dialysis membrane with a 6-8,000 mol wt cut-off against 1 L normal saline and mixed with CFA adjuvant (Difco Laboratories) for the first injection, or IFA adjuvant (Sigma Chemical Co.) for the second injection 3 wk later. The injection sites of the guinea pigs were washed with 70% ethanol and the animals were then injected subcutaneously with 40, 10, 2.5, or 0.6 Rg ofMSP in a total volume of 2001al. Control animals were sham immunized at the same time with normal saline only in CFA (first injection) or in IFA (second injection) . One group of animals immunized with 401ig of MSP in CFA was monitored daily for 5 d for fever, weight loss, or signs of illness .
Immunization of Guinea Pigs with a Sublethal Dose of L. pneumophila. Guinea pigs were immunized by exposure to aerosols of bacteria in the same lucite aerosol chamber described in detail in a previous study (15) . Guinea pigs were immunized with an aerosol generated from a 10-ml suspension of L. pneumophila containing 2.5 x 107 CFU/ml.
ELISA for Antibody to MSP. The humoral immune response of guinea pigs to MSP was assessed by an ELISA assay. MSP in BEN was dialyzed at VC in a dialysis membrane with a 6-8,000 mol wt cut-off against 1 L of0.01 M Tris, 0.1 M NaCl, 0 .0270 sodium azide, pH 7.2, diluted to a concentration of 5 jAg/ml in this buffer, and applied (50 ul/well) to NuncImmuno Plates (Nunc Products, Thousand Oaks, CA) . The plates were covered with an acetate plate sealer (Flow Laboratories Inc., McClean, VA), incubated overnight at room temperature, and stored at 4°C . The plates were washed five times with 0.01 M Tris, 0.1 M NaCl, 3% BSA, 0.02% sodium azide, pH 7 .5 (TNB), blocked with this buffer for 1 h, and tapped dry. Guinea pig sera were diluted from 1 :8 to 1 :2048 in TNB, 50 h.l of each dilution was added per well, and the plates were incubated for 1 h at room temperature with gentle shaking. The plates were washed five times with TNB, tapped dry, and 50 hl of a 1 :1,000 dilution ofalkaline phosphatase-conjugated goat anti-guinea pig IgG (whole molecule) (Sigma Chemical Co.) was added per well. The plates were incubated for 1 h at room temperature with gentle shaking, washed five times with TNB, and tapped dry. A reaction mix containing one p-nitrophenyl phosphate tablet per 5 ml of 20% diethanolamine was prepared with an alkaline phosphatase substrate kit (Bio-Rad Laboratories, Richmond, CA), and 125 hl added per well for 15 min. Blank wells were treated with reaction mix only. The reaction was halted with 50 Al per well of 0.6 M NaOH. The OD of wells was read at 405 nm on a Titertek Multiskan (Flow Laboratories) and a corrected OD was calculated by subtracting the mean of the OD of the blank wells from the OD of each experimental well. The threshold above which titers were considered positive was established in three independent experiments by measuring the OD ofthree different categories ofcontrol wells in each experiment. The control wells contained (a) MSP ; no primary antibody; and conjugated antibody ; (b) no MSP ; primary antibody (six different sera tested) diluted from 1 :32 to 1 :1,024 ; and conjugated antibody; or (c) no MSP; no primary antibody ; and conjugated antibody. For each of the three categories of control wells, a value equal to the mean of the corrected OD readings plus two times the standard deviation was calculated in each of the three experiments . The mean of these nine values was designated as the threshold, and experimental measurements above this threshold were considered positive. The titer of each animal's serum was expressed as the reciprocal of the highest dilution yielding a positive measurement . Negative controls were included on each experimental plate to monitor nonspecific reactions and positive controls were included to allow comparisons among plates . All sera were tested in duplicate, and the geometric mean of the reciprocal titers was calculated .
Cutaneous Delayed-type Hypersensitivity Assay. Guinea pigs were shaved over the back and flank, and administered 100 ,u1 of various concentrations of MSP diluted in EYB, and 100 j1 of control buffer (EYB) intradermally. The diameters of erythema and induration were measured at 24 h and 48 h after injection .
Lymphocyte Proliferation Assay. Splenic lymphocytes from guinea pigs immunized by injection with MSP or by sublethal infection, or from control guinea pigs, were obtained and purified, incubated with MSP in triplicate microtest wells for 2 d, and then tested for their capacity to incorporate [ 3 H]thymidine as described (15) .
Studies of Protective Immunity. Guinea pigs immunized with MSP and sham-immunized control guinea pigs were challenged 3 wk after the second immunization with a lethal aerosolized dose (LD) of L . pneumophila . This dose, which was generated from a 10-ml suspension of L. pneumophila containing 2 .5 x 108 CFU/ml, was the lowest dose that consistently resulted in the death of nonimmunized guinea pigs, and it was determined as previously described (15) . In the first three experiments, the animals were challenged with 1 LD, and in the last two experiments, the animals were challenged with 2 LD. After a 7-d observation period, the survivors were quantitated, and differences in survival between immunized and control animals were evaluated by the Fisher's exact test, two-tailed .
Quantitation of L . pneumophila in Pulmonary Tissue. In two independent experiments, guinea pigs were immunized with MSP at 3-wk intervals or sham immunized (controls), as described above . 3 wk after the second immunization, the guinea pigs were challenged with 1 LD. At various time points 1-72 h after challenge, one immunized and one control animal were killed by hypercarbia . The animals were soaked first in 7 x cleaning solution (Linbro Chemical Co ., New Haven, CT) and second in 70°Jo ethanol to decontaminate their skin, and then the right lung of each animal was removed by sterile technique . Each lung was placed in 10 ml of sterile EYB and ground thoroughly with a mortar and pestle as described (13) . CFU in each lung was determined by plating dilutions of this lung suspension in triplicate on CYEA . The lung suspension was also cultured on sheep blood agar and CYEA without cysteine to check for the presence of contaminating bacteria ; none of the lungs were contaminated with other bacteria .
Results

Purification of MSP.
We purified MSP by a three-step process involving ammonium sulfate precipitation, molecular sieve chromatography, and ion-exchange chromatography. To assess the purity of MSP, we examined it by SDS-PAGE, loading 40 /Ag on a gel and staining with Coomassie Blue (Fig. 1) , and loading 10 ug on a gel and silver staining (19) . By both techniques, we obtained a single band of 39,000 apparent mol wt, suggesting a high degree of purity.
We assayed proteolytic activity at each step of the purification process ( Table 1 ) .
The proteolytic activity per mass increased from 0.021 TU/p,g in the unconcentrated supernatant to 1 .6 TU/,ug after ion-exchange chromatography, the final step in purification . The amount of proteolytic activity after ion-exchange chromatography indicated a 20% yield from the initial amount of proteolytic activity in the unconcentrated supernatant . (Table II , part 1), we compared four animals immunized with a sublethal aerosol dose of L. pneumophila with three control animals, and in four experiments (Table II , part II), we compared four animals immunized with MSP with four control animals. We performed the lymphocyte proliferation assay 3-5 wk after sublethal dose immunization, and 4 wk after the second immunization with MSP Immunized animals exhibited greater lymphocyte proliferative responses to MSP than control animals (Table II) . Three of four guinea pigs immunized with a sublethal aerosol dose of L. pneumophila (Table II , part I) and all four guinea pigs immunized with MSP (Table II, Proteolytic Activity at Stages in the Purification of MSP MSP of L. pneumophila was purified from unconcentrated culture supernatant as described in the text . At each stage in the purification process, the mass of the preparation was measured by the BCA protein assay and the proteolytic activity was determined by the hide powder azure assay. immunized or MSP-immunized guinea pigs develop a cutaneous delayed-type hypersensitivity response to MSP, we injected them intradermally with various concentrations of MSP 3 wk after immunization and measured the extent of erythema and induration at the skin test sites. Both sublethal dose-immunized and MSP-immunized animals consistently had greater mean areas of erythema and induration than control animals (Table III) .
Sublethal dose-immunized animals exhibited mean diameters of erythema and induration of 15 .2 and 7.8 mm, respectively, 24 h after intradermal injection of MSP, compared with 2.0 and 0.0 mm, respectively, in control animals (Table III, Exp. A) . Mean diameters of erythema and induration after intradermal injection of buffer control were minimal in both immunized and control animals.
MSP-immunized animals were skin tested at 24 and 48 h after injection with 100 ul of 1 Wg/ml of MSP (Table 111 , Exp. B) . At 24 h, MSP-immunized animals exhibited mean diameters of erythema and induration of 17 .2 and 6.0 mm, respectively, compared with 3.3 and 1.0 mm, respectively, in control animals . By 48 h, skin responses in both groups of animals had waned, but the stronger responses of animals in the immunized group were still evident . MSP-immunized and control animals were also skin tested with 100-,l injections of MSP over a range of concentrations (0 .5, 5, and 50 Ag/ml) (Table III, Exp. C) . Both groups of animals exhibited dose-dependent skin responses, but at all three concentrations of MSP, the MSP-immunized animals exhibited much greater areas of erythema and induration than control animals.
In both types of experiments with MSP-immunized animals, intradermal injection of diluting buffer did not produce either erythema or induration in either immunized or control animals (Table III) .
MSP-immunized but not Sublethal Dose-immunized Guinea Pigs Develop a Humoral Immune Response to MSP. To determine if guinea pigs immunized with either a sublethal aerosol dose of L. pneumophila or MSP develop a humoral immune response to MSP, we assayed anti-MSP antibody by an ELISA assay, using purified MSP as the capture antigen, guinea pig sera as the source of primary antibody, and alkaline phosphatase-conjugated goat anti-guinea pig IgG as the secondary antibody (Fig . 2) . None of the sublethal dose-immunized guinea pigs developed a humoral immune response to MSP; all four such animals and three control animals had reciprocal antibody titers of <8 (Fig . 2 A) . In contrast, all six MSP-immunized guinea pigs developed a strong humoral response to MSP; their titers ranged from 45 to >2,048, In one experiment (A), guinea pigs were immunized with a sublethal aerosol dose of L . pneumophila or they
were not immunized (controls) . In two other independent experiments (B and C), guinea pigs were immunized subcutaneously with MSP or sham immunized as in Table II . 3 while five of six control guinea pigs had titers of <16 (Fig. 2 B) . A single control guinea pig exhibited a high titer to MSP; this was possibly due to the presence of a crossreactive antibody in this animal . Thus, while MSP-immunized animals developed both a cell-mediated and humoral immune response to MSP, the sublethal dose-immunized animals developed only a cell-mediated immune response . MSP-immunized but not sublethal dose-immunized guinea pigs develop a humoral immune response to MSP. In studies depicted in A, four guinea pigs were immunized with a sublethal dose of L . pneumophila and three control guinea pigs were not immunized . In studies depicted in B, six guinea pigs were immunized with MSP and six were sham immunized, as in Table III . 3 wk later, serum was obtained from each animal and assayed for antibody to MSP by ELISA . All sera were tested in duplicate, and the geometric mean of the reciprocal titers was clultd . All dplittitrithiacaeucae ers wee wn one In five independent experiments, guinea pigs were immunized subcutaneously with MSP or sham immunized as described in Table II . 3 The difference in survival between MSP-immunized and control animals was highly significant (p = 7 x 10 1°, Fisher's exact test, two-tailed) .
Of the MSP-immunized animals challenged with 1 LD, 13 (87%) of 15 survived, whereas of the MSP-immunized animals challenged with 2 LD, 8 (73%) of 11 survived. This difference was not statistically significant by the Fisher's exact test, twotailed .
Guinea pigs immunized with MSP first exhibited signs of illness, including fever, decreased activity, decreased feeding, and respiratory distress, 1 d after challenge, but they then recovered. Nonimmunized animals first exhibited these signs of illness 2 d after challenge, but they did not recover. All animals surviving by 7 d after challenge recovered fully from earlier signs of disease.
Protection against Lethal Aerosol Challenge with L. pneumophila by Immunization with MSP is Dose-dependent. To determine if lower doses of MSP could induce protective immunity in guinea pigs, we immunized animals with 40, 10, 2.5, or 0.6 jug of MSP, and then challenged them with 2 LD of L. pneumophila. As in previous studies, we immunized all animals twice, 3 wk apart, and sham-immunized control animals. We performed two independent experiments (Table V) .
MSP induced protective immunity in dose-dependent fashion in both experiments. tested, appeared to induce some protection, but the level of significance was not high (p = 0.1). Guinea Pigs Immunized with MSPSuppress Multiplication ofL. pneumophila in the Lung. To determine the extent of L. pneumophila multiplication in the lung of MSP-immunized guinea pigs, we challenged 5 MSP-immunized and five control guinea pigs with 1 LD of L. pneumophila, killed them 1-72 h later, and determined CFU of L. pneumophila in the right lung . We performed two independent experiments (Fig . 3) . At 1 h after aerosol exposure, immunized and control animals had similar numbers of L. pneumophila in their lungs in both experiments. By 24 h, CFU markedly increased (2 logs) in both immunized and control animals, but the rate of growth was the same so that both groups had comparable numbers of bacteria in the lung at this time point. Thereafter, CFU in immunized animals plateaued, whereas CFU in control animals continued to increase. By 4$ h, CFU of L. pneumophila in controls was 0.6-0 .7 logs greater than in immunized animals, and by 72 h, CFU of L. pneumophila in controls was 1.4 logs greater than in immunized animals.
Discussion
We have demonstrated that immunization of guinea pigs with the MSP of L. pneumophila induces a highly significant level (p = 7 x 10 -1°) of protective immunity against lethal challenge with an aerosolized dose of L. pneumophila. The lethal aerosol doses used in this study were much higher than those likely to be encountered by humans in nature . Remarkably, immunization with a single protein of L. pneumophila induces strong protective immunity against this complex intracellular parasite .
Previous studies from this laboratory have shown that immunization of guinea
Time after lethal challenge (h) Time after lethal challenge (h) FIGURE 3 . In two independent experiments, MSP-immunized guinea pigs and controls were challenged with one lethal dose of aerosolized L. pneumophila . At the time points indicated, one immunized and one control animal were killed . CFU of L. pneumophila in the right lung of each guinea pig was determined as described in the text . Each point represents the mean t SEM of triplicate measurements of each lung. pigs by the respiratory route with a sublethal dose of L. pneumophila (15) , or with an avirulent mutant strain of L. pneumophila that survives but does not multiply in human monocytes (16) , induces protective immunity. The present study demonstrates that immunization of guinea pigs by the subcutaneous route with MSP also can induce protective immunity. MSP is a very potent inducer of protective immunity against lethal aerosol challenge. As little as 2 .5 p,g, injected twice over a 3 wk interval, was capable of inducing a significant level of protective immunity against 2 LD of L. pneumophila (p = 0 .01, Fisher's exact test, two-tailed) and even two injections of 0.6 wg MSP appeared to induce some protection . In this series of experiments, over the range 0.6 to 40 Ag of MSP, two injections of 40 tag MSP gave the highest level of protection .
Guinea pigs immunized with MSP and then challenged with a lethal dose of aerosolized L. pneumophila limited L. pneumophila multiplication in their lungs. In both immunized and control animals, L. pneumophila multiplied in the lungs during the first 24 h after challenge. Thereafter, CFU in the lungs of control animals continued to increase, while CFU in the lungs of immunized animals plateaued. These results were similar to those obtained in studies of animals immunized with a sublethal dose of L. pneumophila and control guinea pigs (15) . These results suggest that protective immune defenses are marshalled during the first 24 h after challenge. This time period corresponds roughly to that required for lymphokines to activate human mononuclear phagocytes (6) . Such activated monocytes and alveolar macrophages strongly inhibit the intracellular multiplication of L. pneumophila (5) (6) (7) (8) (9) .
Consistent with the idea that immunized guinea pigs marshall immune defenses during the first 24 h after challenge, immunized but not control guinea pigs developed signs of illness during this period . This may reflect an early immune response to L. pneumophila in immunized animals, who generally recovered from the infection . In contrast, control animals developed signs of illness later after challenge and succumbed to the infection.
Both guinea pigs immunized with a sublethal dose of L. pneumophila and guinea pigs immunized with MSP developed a cell-mediated immune response to MSP However, only MSP-immunized animals developed a humoral immune response to MSP. Both groups of immunized animals exhibited strong protective immunity. This suggests that antibody against MSP is not important to host defense but that a cell-mediated immune response to MSP may be . Although previous studies indicate that cell-mediated immunity is of primary importance to host defense against L. pneumophila after natural infection, it is possible that anti-MSP antibody is also playing a role in the protective immunity induced by MSP immunization .
That both sublethal dose-immunized and MSP-immunized guinea pigs develop a cell-mediated immune response to MSP, but only MSP-immunized animals develop a humoral immune response to this molecule, suggests the possibility that antigen processing of MSP differs according to how the molecule is presented to the immune system . In guinea pigs immunized by sublethal dose, MSP produced by L. pneumophila within mononuclear phagocytes may be processed intracellularly such that only small linear determinants are presented to lymphocytes. Such determinants may induce cellular immune responses, which are frequently directed toward unfolded linear epitopes, but not humoral immune responses, which are frequently directed toward a tertiary structure of nondenatured antigen (22) (23) (24) . In contrast, in guinea pigs immunized subcutaneously with MSP, both primary and tertiary structures may be presented to lymphocytes, allowing both cell-mediated and humoral immune responses.
If, indeed, native or processed MSP is released by mononuclear phagocytes or presented on their surface, then the immune system would have a mechanism for detecting intracellular L. pneumophila . Thus, immune lymphocytes that recognize MSP epitopes might proliferate and release lymphokines such as IFN-'Y that are capable of activating the infected mononuclear phagocyte and endowing it with the capacity to inhibit the multiplication of intracellular L. pneumophila (8, 9) . By analogy, secretory molecules of intracellular pathogens may in general allow the immune system to detect parasites sequestered in an intracellular site and thereby to defend the host against them . Along these lines, the intracellular bacterial pathogens Listeria monocytogenes and Mycobacterium tuberculosis release molecules into broth culture that stimulate a cellular immune response (25, 26) .
The finding that the MSP is capable of inducing protective immunity against L. pneumophila infection was arrived at by (a) establishing an animal model suitable for studying cell-mediated and protective immunity (15) ; (b) systematically examining L. pneumophila molecules for their capacity to induce cell-mediated immunity (17) ; and (c) testing such immunostimulatory molecules for their capacity to induce protective immunity. This approach might similarly reveal protective antigens of other intracellular pathogens for which cell-mediated immunity plays an important role in host defense.
A vaccine against an intracellular pathogen consisting of a secretory molecule potentially has two important advantages over a conventional vaccine, consisting of whole organisms or their surface components . First, it may more readily allow the immune system to detect pathogens sequestered in an intracellular site, as noted above. Second, it should be less likely to induce antibody to surface molecules of the pathogen . Such antibody might promote uptake of the pathogen into mononuclear phagocytes, where the organism multiplies, and thereby be counter-productive to host defense.
Summary
We have examined the capacity of the major secretory protein (MSP) of Legionella pneumophila to induce humoral, cell-mediated, and protective immunity in a guinea pig model of Legionnaires' disease. MSP was purified to homogeneity by ammonium sulfate precipitation, molecular sieve chromatography, and ion-exchange chromatography. The purified MSP was nonlethal and nontoxic to guinea pigs upon subcutaneous administration .
Guinea pigs immunized with a sublethal dose of aerosolized L. pneumophila or a subcutaneous dose of MSP developed a strong cell-mediated immune response to MSP. Such guinea pigs exhibited marked splenic lymphocyte proliferation and cutaneous delayed-type hypersensitivity to MSP in comparison with control animals.
Guinea pigs immunized with MSP also developed a strong humoral immune response to MSP, as assayed by an ELISA. The median reciprocal antibody titer was 362 (range 45 to >2,048) for immunized animals compared with <8 for controls . In contrast, guinea pigs immunized with a sublethal dose of L. pneumophila failed to develop anti-MSP antibody.
Guinea MSP, an extracellular protein of an intracellular pathogen, has potential as a vaccine for the prevention of Legionnaires' disease . Secretory molecules of other intracellular pathogens may also have vaccine potential .
